Published in Apoptosis on November 01, 2011
The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma. Springerplus (2014) 1.46
Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun (2015) 1.01
TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo. Neuro Oncol (2012) 0.88
PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma. PLoS One (2014) 0.82
Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines. PLoS One (2014) 0.80
Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors. Stem Cells (2015) 0.79
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science (1992) 19.30
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res (2004) 14.73
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer (2006) 8.50
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res (2007) 6.21
A unified model for apical caspase activation. Mol Cell (2003) 6.12
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia (2002) 5.81
The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42
Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene (2004) 4.29
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol (1999) 4.15
Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells (2007) 3.47
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med (2001) 2.87
TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol (2000) 2.80
Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg (2007) 2.43
FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J Biol Chem (1997) 2.29
Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst (2007) 2.23
Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells (2009) 2.10
Interdimer processing mechanism of procaspase-8 activation. EMBO J (2003) 2.03
Insights into the regulatory mechanism for caspase-8 activation. Mol Cell (2003) 2.01
TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials (2009) 1.73
Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res (2001) 1.71
Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res (2001) 1.70
Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology (2003) 1.56
mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol (2005) 1.56
Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem (2002) 1.54
Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res (2000) 1.47
Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun (1999) 1.33
Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol (2001) 1.23
CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res (2005) 1.20
Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene (2001) 1.15
Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res (2001) 1.10
DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. J Cell Mol Med (2009) 1.09
TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol (2003) 1.06
Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy. Clin Cancer Res (2006) 0.93
Heat shock protein 90alpha recruits FLIPS to the death-inducing signaling complex and contributes to TRAIL resistance in human glioma. Cancer Res (2007) 0.89
Assignment of CASP8 to human chromosome band 2q33-->q34 and Casp8 to the murine syntenic region on chromosome 1B-proximal C by in situ hybridization. Cytogenet Cell Genet (1998) 0.78
Wake-up call for British psychiatry. Br J Psychiatry (2008) 10.30
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin (2010) 5.53
An integrative approach for in silico glioma research. IEEE Trans Biomed Eng (2010) 4.55
MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell (2003) 4.52
An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities. Genet Med (2011) 3.51
The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol (2005) 3.42
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res (2004) 2.79
Integrated morphologic analysis for the identification and characterization of disease subtypes. J Am Med Inform Assoc (2012) 2.68
Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol (2003) 2.67
Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis (2002) 2.53
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46
Relative burden of large CNVs on a range of neurodevelopmental phenotypes. PLoS Genet (2011) 2.46
Real-time magnetic resonance-guided stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy. Neurosurgery (2014) 2.41
Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res (2006) 2.40
Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol (2010) 2.38
CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem (2002) 2.37
Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol (2005) 2.32
The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neurooncol (2014) 2.32
Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci U S A (2002) 2.29
Diagnosis of malignant glioma: role of neuropathology. J Neurooncol (2008) 2.23
Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest (2007) 2.22
The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 2.13
Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J Am Acad Dermatol (2002) 2.05
Double trisomy. Am J Med Genet A (2004) 1.99
Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res (2009) 1.97
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.96
The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One (2010) 1.86
A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov (2012) 1.77
MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology (2013) 1.77
TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials (2009) 1.73
Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. Biotechniques (2008) 1.72
The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.70
Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One (2010) 1.70
Cancer susceptibility variants and the risk of adult glioma in a US case-control study. J Neurooncol (2011) 1.69
Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res (2005) 1.67
Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum (2008) 1.64
Integrative, multimodal analysis of glioblastoma using TCGA molecular data, pathology images, and clinical outcomes. IEEE Trans Biomed Eng (2011) 1.63
Machine-based morphologic analysis of glioblastoma using whole-slide pathology images uncovers clinically relevant molecular correlates. PLoS One (2013) 1.62
Sentinel lymph node mapping for thick (>or=4-mm) melanoma: should we be doing it? Ann Surg Oncol (2003) 1.56
Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem (2002) 1.54
Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution. Am J Surg Pathol (2006) 1.52
Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. J Am Acad Dermatol (2004) 1.52
Molecular classification of renal tumors by gene expression profiling. J Mol Diagn (2005) 1.52
Open biopsy in patients with acute progressive neurologic decline and absence of mass lesion. Neurology (2010) 1.49
Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray. Hum Pathol (2009) 1.49
Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2/neu, and proliferation (MIB-1). Hum Pathol (2004) 1.47
CONFAC: automated application of comparative genomic promoter analysis to DNA microarray datasets. Nucleic Acids Res (2004) 1.44
Non-atherosclerotic fusiform cerebral aneurysms. Can J Neurol Sci (2002) 1.42
Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res (2009) 1.39
Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem (2003) 1.39
Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes. Exp Neurol (2004) 1.36
Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis. Cancer Res (2003) 1.34
Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol (2005) 1.34
RBPJ mutations identified in two families affected by Adams-Oliver syndrome. Am J Hum Genet (2012) 1.34
Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res (2009) 1.33
Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res (2007) 1.31
Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Mol Cancer Res (2008) 1.30
Defining the expression pattern of the LGI1 gene in BAC transgenic mice. Mamm Genome (2007) 1.25
The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol (2012) 1.25
Cryosurgery planning using bubble packing in 3D. Comput Methods Biomech Biomed Engin (2008) 1.25
Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy. Am J Pathol (2011) 1.24
Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene (2005) 1.23
Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res (2006) 1.23
Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology (2010) 1.23
Cancer-specific loss of beta-defensin 1 in renal and prostatic carcinomas. Lab Invest (2003) 1.22
Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion. Proc Natl Acad Sci U S A (2008) 1.22
Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res (2009) 1.22
Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci U S A (2004) 1.22
Interferon gamma induces neurite outgrowth by up-regulation of p35 neuron-specific cyclin-dependent kinase 5 activator via activation of ERK1/2 pathway. J Biol Chem (2005) 1.22
Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake. Am J Nucl Med Mol Imaging (2013) 1.21
Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol (2003) 1.21
Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology (2010) 1.20
Molecular characterization of the t(3;9) associated with immortalization in the MCF10A cell line. Cancer Genet Cytogenet (2005) 1.20
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res (2004) 1.19
Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer. Cancer Res (2008) 1.19
Towards intra-operative computerized planning of prostate cryosurgery. Int J Med Robot (2007) 1.18
Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm (2010) 1.17
The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol (2003) 1.17
DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model. J Exp Med (2007) 1.16
Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer (2002) 1.16
MORPHOLOGICAL SIGNATURES AND GENOMIC CORRELATES IN GLIOBLASTOMA. Proc IEEE Int Symp Biomed Imaging (2011) 1.16
Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Appl Immunohistochem Mol Morphol (2010) 1.15
Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med (2008) 1.15
The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.13
Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol (2007) 1.12
AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol (2007) 1.12
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro Oncol (2002) 1.12
Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg (2008) 1.12
Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis. Mol Cancer Ther (2007) 1.11
Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J Neurosci (2006) 1.11
TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2. J Vasc Res (2005) 1.10
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol (2010) 1.10